Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has announced early clinical research results for three drugs in the cell cycle protein-dependent kinase inhibitor (CDKi) field, which were presented at the European Society for Medical Oncology (ESMO) annual meeting [1] Group 1: Company Performance - The stock price of Tongyuan Kang Pharmaceutical-B increased by over 3% at the beginning of trading and is currently up by 1.52%, trading at 15.40 HKD with a transaction volume of 18.24 million HKD [1] Group 2: Clinical Research and Events - The three drugs highlighted are TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), which are part of the company's strategic focus [1] - The ESMO 2025 annual meeting will take place from October 17-21, 2025, in Berlin, Germany, and is recognized as one of the most influential academic events in the oncology field, attracting top experts and scholars [1]
同源康医药-B盘初涨超3% TYK-00540等多项CDK抑制剂临床积极数据于ESMO2025...